- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03860818
Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention (ISTEP)
Improving Transplant Medication Safety Through a Technology and Pharmacist (ISTEP) Intervention in Veterans
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Anticipated Impacts on Veterans Health Care: The first three essential strategies listed within the VA's Blueprint for Excellence encompass plans to improve care to vulnerable Veterans, deliver high quality care through achieving the "Triple Aim" and leverage the use of technology to improve the efficiency of care delivery. The intervention this grant proposes focuses on improving medication safety and care coordination within a high risk vulnerable Veteran population, leverages the use of informatics and analytics to support this intervention, and aims to demonstrate improved care at reduced costs through the pharmacist intervention; thus, perfectly aligning with these three essential components of the Blueprint. The overarching goal of this study is to develop a feasibly deployable, technology-enabled intervention that will demonstrate substantial improvements in immunosuppressant medication safety, clinical outcomes and health care costs in Veteran organ transplant recipients; demonstrating this through a randomized controlled trial will provide sufficient evidence to further develop a VA-specific pharmacist learning collaborative aimed at improving care and reducing costs for Veteran organ transplant recipients across the entire VA system.
Background: Organ transplant is the gold-standard treatment for patients with end organ diseases of the kidney, liver, heart and lungs, as it substantially improves survival and quality of life. Over the past 20 years, the use of contemporary immunosuppression has reduced the risk of acute rejection rates by upwards of 80%; yet long-term allograft survival remains suboptimal. Studies have demonstrated that causes of late graft loss is predominantly driven by immunosuppression adverse events and late allograft rejection episodes from medication errors and non-adherence, which encompass issues directly related to medication safety. The investigators' research demonstrates that medication errors occur in nearly two-thirds of transplant recipients, leading to hospitalization in 1 in 8 recipients. Recipients that develop significant medication errors are at considerably higher risk of graft loss, leading to higher costs and mortality. Thus, in order to improve medication safety and long-term outcomes in transplant recipients, enhancements in immunosuppressant therapy management is needed.
Objectives: The central hypothesis for the ISTEP study (Improving Transplant Medication Safety through a TEchnology and Pharmacist Intervention) is that pharmacist-led immunosuppressant therapy management, facilitated through the use of innovative technology, will significantly improve immunosuppressant safety and clinical outcomes in Veteran transplant recipients.
Methods: This is a 24-month, prospective, cluster-randomized controlled clinical trial at 10 sites, randomizing 5 sites to standard clinical care and 5 to standard care and the technology-enabled pharmacist intervention. The technology component of this intervention consists of the use of an expanded dashboard system that has already demonstrated effectiveness in improving immunosuppression monitoring. The dashboard performs population-level surveillance of transplant recipients and identifies those with potential drug-related problems, including non-adherence, drug interactions, missing and worrisome trends in labs; then providing a real-time alert to the pharmacist, who will determine its relevance and intervene in an appropriate protocol-guided manner. Effectiveness will be determined by comparing the rates of hospitalizations and ER visits between groups, while adjusting for baseline patient, provider and facility characteristics. Secondary measures include comparing healthcare costs and determining dashboard functionality, dashboard actionability and pharmacist intervention types and acceptance rates. The investigators will also assess the overall incidence and severity of drug-related problems and graft and patient survival rates and compare these between the intervention and control sites.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
South Carolina
-
Charleston, South Carolina, Yhdysvallat, 29401-5799
- Ralph H. Johnson VA Medical Center, Charleston, SC
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Veteran organ transplant recipients will be identified using ICD-9/10 codes from the VA electronic health record (CPRS).
- Patients must have an active code stating they are a recipient of an organ transplant.
The following codes will be utilized - oICD-9 codes:
- V42.0
- V42.1
- V42.6
- V42.7
- V42.83
- V42.84
- 996.81
- 996.82
- 996.83
- 996.84
- 996.86
- 52.80
OR
oICD-10 codes:
- C80.2
- T86.1
- T86.10
- T86.11
- T86.12
- T86.13
- T86.19
- T86.2
- T86.20
- T86.21
- T86.22
- T86.23
- T86.290
- T86.298
- T86.3
- T86.30
- T86.31
- T86.32
- T86.33
- T86.39
- T86.4
- T86.40
- T86.41
- T86.42
- T86.43
- T86.49
- T86.810
- T86.811
- T86.812
- T86.818
- T86.819
- T86.9
- Z48.2
- Z48.21
- Z48.22
- Z48.23
- Z48.24
- Z48.280
- Z48.288
- Z48.298
- Z94.0
- Z94.1
- Z94.2
- Z94.3
- Z94.4
- Z94.83
AND
- Actively receiving at least one anti-rejection medication dispensed by the VA site.
These medications include:
- tacrolimus
- cyclosporine
- azathioprine
- mycophenolate
- sirolimus
- everolimus
- belatacept
Exclusion Criteria:
- There are no exclusion criteria for patients in this study as recruitment is at the level of the VA site.
- All veterans meeting inclusion criteria will be monitored by the dashboard system and will be included in the outcomes assessment.
- Patients may enter or exit the study in a rolling manner, which will be accounted for during analyses.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Terveyspalvelututkimus
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Ei väliintuloa: Control Arm
Usual Care
|
|
Kokeellinen: Intervention Arm
Technology-enabled pharmacist intervention
|
Technology-enabled pharmacist intervention
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Rate of hospitalization and emergency room visits
Aikaikkuna: 24-months
|
24-month rate of hospitalization and emergency room visits compared between the intervention and usual care groups
|
24-months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Total estimated health care costs
Aikaikkuna: 24-months
|
24-month total estimated health care costs, compared between the intervention and usual care groups
|
24-months
|
Graft survival
Aikaikkuna: 24-months
|
Estimated graft survival rates, compared between the intervention and usual care groups and defined as the proportion of patients that continue to have a functioning allograft at the end of the 24-month study
|
24-months
|
Patient survival
Aikaikkuna: 24-months
|
Estimated patient survival rates, compared between the intervention and usual care groups and defined as the proportion of patients alive at the end of the 24-month study
|
24-months
|
Medication safety issues
Aikaikkuna: 12-months
|
Potential medication safety issues, defined as the proportion of patients with the following, based on automated reports for the transplant medication dashboard
|
12-months
|
Clinical relevant alerts
Aikaikkuna: 12-months
|
Proportion of alerts that were deemed clinical relevant and actionable by the intervention pharmacists
|
12-months
|
Accepted interventions
Aikaikkuna: 12-months
|
Proportion of interventions that were deemed to be accepted when made to other providers based on dashboard reporting information
|
12-months
|
Time requirements
Aikaikkuna: 12-months
|
Average time each intervention pharmacist spent on assessing the dashboard alerts
|
12-months
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: David J. Taber, PharmD, Ralph H. Johnson VA Medical Center, Charleston, SC
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Taber DJ, Ward R, Axon RN, Walker RJ, Egede LE, Gebregziabher M. The Impact of Dual Health Care System Use for Obtaining Prescription Medications on Nonadherence in Veterans With Type 2 Diabetes. Ann Pharmacother. 2019 Jul;53(7):675-682. doi: 10.1177/1060028019828681. Epub 2019 Feb 6.
- Hall CL, Fominaya CE, Gebregziabher M, Milfred-LaForest SK, Rife KM, Taber DJ. Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc. 2019 Oct 1;8(10):e13821. doi: 10.2196/13821.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- IIR 15-359
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Elinsiirto
-
Abramson Cancer Center of the University of PennsylvaniaPeruutettuSyöpäpotilaat, joille tehdään kantasolusiirto (RCT of ACP for Transplant)
-
Providence Health & ServicesUniversity of Washington; Ochsner Health System; The Heart Institute of SpokaneValmisTransplant Bone DiseaseYhdysvallat
-
University of ChicagoLopetettuKrooninen hyljintä keuhkosiirrossa | Sytokiinien tuotanto Bosissa Post Lung TransplantYhdysvallat
Kliiniset tutkimukset Health services delivery
-
Wake Forest University Health SciencesValmisTakaisinotto sairaalaanYhdysvallat
-
Emory UniversityValmisGlaukooma | Silmänpohjan rappeuma | KaihiYhdysvallat
-
Hunter College of City University of New YorkRekrytointi
-
Montefiore Medical CenterBeyond MeatEi vielä rekrytointia
-
RxSight, Inc.Valmis
-
Medtronic Neurovascular Clinical AffairsValmisValtimolaskimon epämuodostumatYhdysvallat
-
Unity Health TorontoTuntematon
-
Brigham and Women's HospitalTuntematon
-
LumiThera, Inc.RekrytointiKuiva ikään liittyvä silmänpohjan rappeumaNorja